Abstract: The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.
Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
Abstract: An ophthalmic solution, which comprises diquafosol tetrasodium salt and is free from benzalkonium chloride, treats onset and/or exacerbation of dry eye symptom caused by wearing soft contact lenses.
Abstract: An ophthalmic solution, which comprises diquafosol tetrasodium salt and is free from benzalkonium chloride, treats onset and/or exacerbation of dry eye symptom caused by wearing soft contact lenses.
Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
Abstract: The object of the present invention is to find a new application of isopropyl (6-{ [4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof. Isopropyl (6-{ [4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminometh yl}pyridin-2-ylamino) acetate or a salt thereof is useful as a therapeutic agent for a disease involving a greatly elevated intraocular pressure.
Type:
Application
Filed:
March 11, 2020
Publication date:
July 2, 2020
Applicant:
SANTEN PHARMACEUTICAL CO., LTD.
Inventors:
Tomoko KIRIHARA, Atsushi SHIMAZAKI, Najam A. SHARIF
Abstract: The present invention aims to find a novel pharmaceutical use of omidenepag, esters thereof, or salts thereof. The present inventors have made intensive studies to find a novel pharmaceutical use of omidenepag, an ester thereof, or a salt thereof, and have found as a result that omidenepag, an ester thereof, or a salt thereof significantly dilates retinal blood vessels, and significantly increases blood flow. Therefore, omidenepag, an ester thereof, or a salt thereof is expected to protect retinal nerve cells and be useful for prevention and/or treatment of ophthalmic diseases involving retinal nerve cell disorder.
Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.
Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.
Abstract: An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10?11 mol/L or less.
Type:
Application
Filed:
January 5, 2017
Publication date:
May 28, 2020
Applicants:
ORDER-MADE MEDICAL RESEARCH INC., SANTEN PHARMACEUTICAL CO., LTD.
Inventors:
Yasufumi MURAKAMI, Shigeki MUKOUBATA, Hirotada AKIYAMA, Koji KONOMI
Abstract: This invention relates to a method for treatment of persistent edema in patients with exudative age-related macular degeneration. In particular, the present invention relates to treatment of wet age-related macular degeneration with intravitreal sirolimus in subjects that had an inadequate response to prior treatment with an intravitreal anti-vascular endothelial growth factor agent.
Abstract: The present invention addresses the problem of providing a novel application of meglumine or a salt thereof. The present invention is an antiseptic agent consisting of meglumine or a salt thereof, and a pharmaceutical composition comprising the antiseptic agent according to the present invention, and pertaining to: a pharmaceutical composition which does not comprise benzalkonium chloride and which is placed in a reusable container; a product that comprises the pharmaceutical composition comprising the antiseptic agent according to the present invention and a reusable container; and a method of improving the antiseptic effect of the pharmaceutical composition by comprising meglumine or a salt thereof in the pharmaceutical composition that has been placed in the reusable container.
Type:
Application
Filed:
March 13, 2017
Publication date:
May 14, 2020
Applicant:
Santen Pharmaceutical Co., Ltd.
Inventors:
Toyomi Fujisawa, Koji Sakanaka, Shinya Umezaki
Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
Abstract: A composition for preventing or treating glaucoma or ocular hypertension including a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl} pyridin-2-ylamino) acetate and at least one other drug for preventing or treating glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.
Abstract: In order to enable long-term stabilization of rapamycin contained in a liquid formulation, a formulation sealing vessel of the present invention includes: a sealed vessel body in which a liquid formulation containing 2% (w/w) rapamycin or a salt thereof, 94% (w/w) polyethylene glycol, and 4% (w/w) ethanol is sealed, the sealed vessel body having a volume of 0.1 mL to 1.0 mL, the liquid formulation containing no antioxidant, and the liquid formulation having a total volume of 0.02 mL to 1.0 mL.
Abstract: The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.
Abstract: The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.
Abstract: The present disclosure relates to methods of treating prostate cancer by administering an effective amount of sirolimus locally to the prostate of a subject in need thereof. In particular, the present disclosure provides methods of treating prostate cancer by intratumoral injection of a liquid formulation comprising sirolimus in which the amount of sirolimus administered is well above the dosage used for preventing transplant rejection.
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.